Top

Published in:

01-12-2010

A Teaching Model for Aromatase Inhibitors After Tamoxifen

Authors: Theresa Trotter, Marc Webster, Cindy Railton, A. H. G. Paterson, Tyrone Donnon

Published in: Journal of Cancer Education | Issue 4/2010

Abstract

Breast cancer is the most common cancer diagnosed in women. The present study evaluated the family physicians' (FPs) understanding of adjuvant hormonal therapies for an early breast cancer. FPs were invited to attend teaching workshops on this topic, which utilized a pretest, didactic and interactive teaching, and posttest format. FPs (n = 23) showed an improvement (p < 0.001) in pretest to posttest score. It is clear that, with a targeted teaching, FPs can quickly become more knowledgeable on the topic of hormonal therapies in breast cancer, with the potential of applying this information in their own practice.

Goss P, Ingle J, Martino S et al (2003) A randomized trial of letrozole in post-menopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med 349:1793–1802CrossRefPubMed

Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in post-menopausal women with primary breast cancer. Intergroup Exemestane Study. N Engl J Med 350:1081–1092CrossRefPubMed

Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in combination) trial after completion of 5 years' adjuvant treatment for cancer. ATAC Trialists' Group. Lancet 365(9453):60–62CrossRefPubMed

Thurlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. Breast International Group (BIG) 1-98 Collaborative Group. N Engl J Med 353:2747–2757CrossRefPubMed

Jakesz R, Jonat W, Gnant M et al (2005) Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABSCG trial 8 and ARNO 95 trial. Lancet 366:455–462CrossRefPubMed

Boccardo F, Rubagotti A, Guglielmini P, et al. (2006) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole Study (ITA) Trial. Ann Oncol 17 Suppl 7:vii10–vii14

Trotter T, Railton C, Webster M et al (2007) Acceptance of extended hormonal therapy with letrozole after 5 years of adjuvant tamoxifen in post-menopausal breast cancer patients. Abstract. Breast Cancer Res Treat 106(Suppl 1):S145

Davis D, O’Brien MA, Freemantle N et al (1999) Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? JAMA 282:867–874CrossRefPubMed

O’Brien MA, Freemantle N, Oxman AD, et al. (2001) Continuing education meetings and workshops: effects on professional practice and health care outcomes. Cochrane Database Syst Rev, Issue 1. Art. no.: CD002020. doi:10.1002/14651858.CD003030

10.

Davis RS, Bukstein DA, Luskin AT et al (2004) Changing physician prescribing patterns through problem-based learning: an interactive, teleconference case-based education program and review of problem-based learning. Ann Allergy Asthma Immunol 93:237–242CrossRefPubMed

11.

White M, Michaud G, Pachev G et al (2004) Randomized trial of problem-based vs didactic seminars for disseminating evidence-based guidelines on asthma management to primary care physicians. J Contin Educ Health Prof 24:237–243CrossRefPubMed

12.

Fordis M, King JE, Ballantyne CM et al (2005) Comparison of the instructional efficacy of internet-based CME with live interactive CME workshops. JAMA 294(9):1043–1051CrossRefPubMed

Title: A Teaching Model for Aromatase Inhibitors After Tamoxifen
Authors: Theresa Trotter
Marc Webster
Cindy Railton
A. H. G. Paterson
Tyrone Donnon
Publication date: 01-12-2010
Publisher: Springer-Verlag
Published in: Journal of Cancer Education / Issue 4/2010
Print ISSN: 0885-8195
Electronic ISSN: 1543-0154
DOI: https://doi.org/10.1007/s13187-010-0095-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

The Annual Summer School in Oncology for Medical Students, Groningen, Holland 2008

Developing and Implementing a Local Education and Support Program for Patients with Gastrointestinal Stromal Tumors (GISTs)

Knowledge About Cancer Screening Among Medical Students and Internal Medicine Residents in Mexico City

A Survey of Head and Neck Cancer Curriculum in United States Speech Language Pathology Masters Programs

Sources of Information that Promote Breast and Cervical Cancer Knowledge and Screening Among Native Hawaiians in Southern California

Oncology Residents’ Perspectives on Communication Skills and Shared Decision Making

Keynote webinar | Spotlight on antibody–drug conjugates in cancer